Atopic dermatitis is a chronic, pruritic, inflammatory skin disease with a wide range of severity. It is one of the most common skin disorders in developed countries, affecting approximately 20% of children and 1-3% of adults. Severe eczematous skin lesion and itching can significantly affect the quality of life of the patient. Best clinical practice in the management of AD requires a multi-therapeutic approach that includes short-term treatment of AD flares and longer-term treatment that control symptoms between flares and prolong the time to next flare. Therapies used include emollients, topical corticosteroid, and topical calcineurin inhibitors (TCIs). Emollients have long been used to maintain the skin barrier function in patients with AD. Topical corticosteroids have been the pillar of medicated therapy for AD since their introduction nearly 50years ago, Topical calcineurin inhibitors represented the first new class of medication approved for the treatment of AD since topical corticosteroid, TCIs provide targeted anti-inflammatory activity without the local or systemic side-effects seen with topical corticosteroid, More recently, three new nosteroidal barrier cream have entered the marketplace for AD treatment. Multiple topical therapies have been successfully used to treat patients with AD. An understanding of the available treatment options will help primary care providers striving to achieve best practice in the management of AD.